Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zach Walsh

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Psychopharmacology|May 9, 2019
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trialsMichael C Mithoefer, Allison A Feduccia, Lisa Jerome, et al.
The Yale Journal of Biology and Medicine|July 2, 2020
The Potential for Kratom as an Antidepressant and AntipsychoticLindsay E Johnson, Lilian Balyan, Amy Magdalany, et al.
Drug and Alcohol Review|October 3, 2019
Guidelines for public health and safety metrics to evaluate the potential harms and benefits of cannabis regulation in CanadaStephanie Lake, Thomas Kerr, Dan Werb, et al.
Experimental and Clinical Psychopharmacology|January 12, 2023
Correlations of kratom (Mitragyna speciosa Korth.) use behavior and psychiatric conditions from a cross-sectional surveyOliver Grundmann, Charles A Veltri, Sara Morcos, et al.
The American Journal of Drug and Alcohol Abuse|April 7, 2022
Exploring the self-reported motivations of kratom (<i>Mitragyna speciosa</i> Korth.) use: a cross-sectional investigationOliver Grundmann, Charles A Veltri, Diana Morcos, et al.
BMC Musculoskeletal Disorders|August 1, 2014
Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaintsMary-Ann Fitzcharles, Peter A Ste-Marie, Daniel J Clauw, et al.
Psychopharmacology|October 10, 2025
Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing daysMichelle St Pierre, Elena Argento, Jordyn Cates, et al.
Journal of Cannabis Research|July 4, 2023
Why a distinct medical stream is necessary to support patients using cannabis for medical purposesCecilia Costiniuk, Caroline A MacCallum, Michael Boivin, et al.
Arthritis Care & Research|November 10, 2015
Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled TrialsMary-Ann Fitzcharles, Peter A Ste-Marie, Winfried Häuser, et al.
Journal of Affective Disorders|January 22, 2019
A longitudinal analysis of cannabis use and mental health symptoms among gay, bisexual, and other men who have sex with men in Vancouver, CanadaFrank Y Chou, Heather L Armstrong, Lu Wang, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Psychopharmacology|May 9, 2019
MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trialsMichael C Mithoefer, Allison A Feduccia, Lisa Jerome, et al.
The Yale Journal of Biology and Medicine|July 2, 2020
The Potential for Kratom as an Antidepressant and AntipsychoticLindsay E Johnson, Lilian Balyan, Amy Magdalany, et al.
Drug and Alcohol Review|October 3, 2019
Guidelines for public health and safety metrics to evaluate the potential harms and benefits of cannabis regulation in CanadaStephanie Lake, Thomas Kerr, Dan Werb, et al.
Experimental and Clinical Psychopharmacology|January 12, 2023
Correlations of kratom (Mitragyna speciosa Korth.) use behavior and psychiatric conditions from a cross-sectional surveyOliver Grundmann, Charles A Veltri, Sara Morcos, et al.
The American Journal of Drug and Alcohol Abuse|April 7, 2022
Exploring the self-reported motivations of kratom (<i>Mitragyna speciosa</i> Korth.) use: a cross-sectional investigationOliver Grundmann, Charles A Veltri, Diana Morcos, et al.
BMC Musculoskeletal Disorders|August 1, 2014
Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaintsMary-Ann Fitzcharles, Peter A Ste-Marie, Daniel J Clauw, et al.
Psychopharmacology|October 10, 2025
Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing daysMichelle St Pierre, Elena Argento, Jordyn Cates, et al.
Journal of Cannabis Research|July 4, 2023
Why a distinct medical stream is necessary to support patients using cannabis for medical purposesCecilia Costiniuk, Caroline A MacCallum, Michael Boivin, et al.
Arthritis Care & Research|November 10, 2015
Efficacy, Tolerability, and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled TrialsMary-Ann Fitzcharles, Peter A Ste-Marie, Winfried Häuser, et al.
Journal of Affective Disorders|January 22, 2019
A longitudinal analysis of cannabis use and mental health symptoms among gay, bisexual, and other men who have sex with men in Vancouver, CanadaFrank Y Chou, Heather L Armstrong, Lu Wang, et al.
Pageof 9